RAYNHAM, Mass.--(BUSINESS WIRE)--Medrobotics Corp., a medical robotics company, today announced that it submitted an application to the FDA for clearance of a flexible transabdominal robotic scope proposed to visualize anatomy in the thoracic and abdominal cavities. This submission reaffirms the Company’s commitment to develop products for single-port general, gynecological, and urological surgeries.
Medrobotics markets the Flex® Robotic System globally for ScarfreeTM ENT and colorectal procedures through natural body orifices. The Company is also pursuing expansion of applications to other areas including transvaginal gynecologic procedures.
Medrobotics Corporation (www.Medrobotics.com) is a privately funded medical device company headquartered in Raynham, Massachusetts. It manufactures and markets the Flex® Robotic System, the world’s first robotic surgical platform with a steerable and shapeable robotic scope. The Flex Robotic System offers surgeons the unique ability to navigate complex anatomy through a single, small entry point while operating in hard-to-reach anatomical locations that might otherwise be inaccessible with straight, rigid surgical tools. The Company’s vision is to provide more patients with access to ScarfreeTM surgical options. Medrobotics received FDA clearances for the Flex Robotic System for ENT applications in July 2015 and for colorectal surgery in May 2017. The CE mark was issued in March 2014.